Hoth Shares Rise After Alzheimer's Treatment Gets Patent

Dow Jones10-15
 

By Stephen Nakrosis

 

Shares of Hoth Therapeutics were trading higher in Tuesday's pre-opening market, following news the company was granted a U.S. patent for its Alzheimer's treatment, HT-ALZ.

The company said it is preparing for clinical trials of HT-ALZ, with formulation currently under way.

Before the bell, the stock had risen 29% to trade at $1.06. Shares last closed above $1 on Sept. 18.

The stock finished Monday's regular session at 82 cents, rising 9% on the day.

The company said its treatment takes a novel approach by targeting the Substance P/Neurokinin-1 Receptor pathway, which is known to play a critical role in neuroinflammation, increasingly recognized as a driving factor in the progression of Alzheimer's disease.

 

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

 

(END) Dow Jones Newswires

October 15, 2024 06:58 ET (10:58 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment